Hepatitis C is a liver disease caused by hepatitis C virus (HCV) infection. Protease inhibitor (PI) is included in the current oral direct-acting antiviral (DAA) combination therapy. However, these HCV PIs are small molecule drugs; therefore, they could have serious off-target adverse effects. New types of treatment such as antibody drugs that have very high specificity and selectivity would be a better alternative. Our study reports the application of the PROTECT (Protease inhibitor Recognition based On Tat Export after Cleavage Tampering) assay, an in vivo detection method for protease inhibiting intracellular antibodies (intrabodies) based on the bacterial twin-arginine translocation (Tat) pathway to the HCV NS3 protease system. This assay was designed such that when protease is co-expressed inside the bacterial cytoplasm, Tat transportation of the uncleaved protease substrate due to protection of the cleavage site by a specific intrabody will result in β-lactam antibiotic resistance. Using the anti-NS3 intrabodies isolated previously, we demonstrated that PROTECT assay could distinguish between the inhibitory and non-inhibitory anti-NS3 intrabodies resulting in selective growth in the presence of β-lactam antibiotics. This method has potential for the screening of agents that inhibit proteolytic cleavage in a bacterial cell-based assay, which may find use in identifying, reconstituting, and characterizing protease inhibitors, identifying mutations on the substrate that can inhibit proteolytic cleavage, and drug screening.
Introduction
Protease inhibitors (PIs) are used to prevent proteolytic cleavage due to proteases, a large enzyme family that catalyzes the proteolysis of a peptide bond. They have been used to treat many disorders and viral infections for many decades. It was estimated that proteases account for 5-10% of all pharmaceutical targets being pursued for drug development *1+. PIs found in nature are commonly proteins or peptides; however, current PI drugs are often synthetic peptide-like or small molecules resembling known protease substrates. For this reason, they can cause off-target effects due to the cross-reactivity of the PI with the homologues of the target protease containing the same catalytic mechanism and analogous substrate specificity, which may be essential to the human body. Moreover, emerging evidence has suggested that the small-molecule PIs have many side effects. It has been evidenced that HIV PIs are associated with metabolic abnormalities such as dyslipidemia, insulin resistance, and lipodystrophy/lipoatrophy, as well as cardiovascular and cerebrovascular diseases *2+. Some PIs may have significant interactions with other drugs. Consequently, macromolecule drugs such as antibody drugs may represent a better alternative to the current small molecule drugs because of their very high specificity and selectivity, which are the main advantages over the current small molecule drugs which are more promiscuous. Therefore, in terms of safety, biologics have low toxicity and thus are known to cause less serious adverse events *3+.
Biotechnological advances allow for large-scale production of biologics in a cost-effective manner. is clear that more drug development for HCV treatment is still needed *7+.
The use of monoclonal antibodies as therapeutic agents has led to the concept of intracellular antibodies or intrabodies. They, basically, are the smaller antibody fragments which are engineered to function inside the cells for the targeting of the intracellular proteins that are the cause of disease. In general, most antibody fragments failed to express or lost their ability to bind to the target antigen when expressed intracellularly as they are naturally produced to function outside cells that have an oxidizing environment.
Therefore, the development of screening or an isolation method of functional intrabodies is important for drug discovery. Gal-Tanamy et al. have developed a genetic screen used for the isolation of single-chain antibodies acting as intrabodies that can neutralize HCV NS3 serine protease. The method is based on the co-expression of the enzyme β-galactosidase (reporter protein), recombinant NS3 protease, and fusion-stabilized single-chain antibody fragment (scFv) in E. coli *8+. Interestingly, they also showed that the isolated anti-NS3 scFvs could inhibit the autonomous amplification of HCV replicons resistant to the small molecule inhibitors of the NS3/4A protease as well as replicons derived from different HCV genotypes *9+. This type of antibody fragment drug may be very useful for the treatment of HCV because it may also be applied as gene therapy in the future, which can reduce the drug resistance rate that occurs when patients often miss drug doses.
The Tat pathway is a secretion pathway commonly found in bacteria and plant thylakoids. It has useful
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unique properties, i.e. the quality control and the hitchhiker mechanisms, which have been applied for the development of many protein engineering platforms *10+-*13+. Our recent work reported the potential of applying the Tat pathway as a tool for the isolation of protease-inhibiting intrabodies, which we later designated PROTECT (Protease inhibitor Recognition based On Tat Export after Cleavage Tampering) [13+.
Using a synthetic biology approach, the in vivo selection system was designed by co-expressing three components, i.e., protease activity detector (tripartite fusion of substrate flanking by a twin-arginine translocation (Tat) signal sequence at its N-terminus and a reporter which is TEM-1 β-lactamase (Bla), an antibiotic resistance protein, at its C-terminus), protease generator (C-terminal His tagged HCV NS3 protease) and protease blocking device (C-terminal FLAG tagged protease-inhibiting intrabody), in the cytoplasm of E. coli. Based on this design, in the presence of the protease and inhibitors, the Tat-specific export of an uncleaved substrate from the cytoplasm into the periplasm resulting in bacterial cell resistance to the β-lactam antibiotic, such as Ampicillin (Amp) and Carbenicillin (Carb), is used to identify candidate inhibitors. This method was applied to the HIV-1 system and showed that the HIV-1 p17 intrabody specific to the C-terminus of p17, an HIV protease substrate, could protect the p17-p24 cleavage site from proteolysis resulting in β-lactam antibiotic resistance.
Materials and Methods

Plasmid Constructions and Bacterial Strains
E. coli strain DH5α was used for all plasmid constructions. The plasmid used for tricistronic expressions was based on pDD18 [11] . The HCV NS3 system was cloned into the tricistronic expression vector, pDD18 (also kindly provided by Itai Benhar) was generated with a C-terminus His tag flanking by HindIII cut sites and cloned to replace HIV-PR::His. All the constructs were sequenced to confirm. 
Selective Growth Assays
Protein Analysis
E. coli strain MC4100 containing both pDD18 and pDD322Kan plasmids were subcultured in fresh LB media at 37°C until the cells reached an OD600 ~0.4-0.5 then induced by adding arabinose to a final concentration of 0.01% wt/vol and protein expression was continued at 30°C and harvested 3 h after induction. Samples were normalized by OD 600 = 75 before being subjected to subcellular fractionation, which was performed using the ice-cold osmotic shock procedure to release periplasmic proteins, followed by sonication to release cytoplasmic proteins [12] . Each fraction was separated by SDS/PAGE and Western blotting was performed according to standard protocols. Membranes were probed with rat anti-FLAG (1:3,000; Sigma-Aldrich) to detect anti-NS3 intrabodies and mouse anti-Bla (1:500; Abcam) to detect the ssTorA::NS5A/B::Bla fusion. Secondary antibodies used were goat pAb anti-rat conjugate HRP (1:5,000;
Abcam) for rat anti-FLAG, and anti-mouse conjugate HRP (1:2,500; PROMEGA) for mouse anti-Bla. The detailed concept of the PROTECT system has been illustrated previously [13] . 
Results and Discussion
Construction of the Detection System
Protease Inhibiting Intrabody Can Block HCV NS3 Catalysis in Vivo
When we first developed the assay, we successfully applied it to the HIV-1 PR system. Here, we aim to demonstrate that PROTECT can be applied to various types of targets. In our previous work, we used the non-interacting intrabody as a negative control, whereas in this current work, we compared between two intrabodies. Both can bind to the protease but one scFv has a catalysis inhibitory effect (scFv 35, used as a positive control) while the other does not (scFv 53Y, used as a negative control). Fig. 2 . illustrates that cells containing scFv 35 clearly showed higher β-lactam antibiotic resistance than the cells containing scFv 53Y.
The positive control showed high cell resistance as a single level colony (10 -6 dilution) could grow even at 1000 µg/mL Carb, which means a large amount of ssTorA::NS5A/B::Bla was transported to the periplasm, probably due to the low solubility of the protease when produced in the cytoplasm of E. coli as reported previously, even though the HCV ΔNS3 construct was used [8] , [14] . For the negative control, a higher induction level and temperature seemed to result in higher background growth, probably because high translation rates can cause the protease to form inclusion bodies resulting in the even lower solubility of ΔNS3. Nonetheless, at the best conditions tested, which were induced with 0.001% arabinose, plated on 1000 µg /mL Carb, and incubated for 24 h, the differences between the positive (grew at 10 -6 dilution) and the negative controls (grew at 10 -3 dilution) are about 1000-fold.
It should be noted that the fundamental difference of this system compared to the HIV system previously reported [13] is that these scFvs target the protease itself while the positive-control scFv in the HIV system targets the substrate of the protease around the cleavage site. Therefore, from these two studies we have established that our PROTECT assay has the potential to identify protease-inhibiting scFvs that can protect against proteolytic cleavage either by binding to the protease or to the substrate thus tampering the cleavage. There are many advantages associated with this assay compared to the typical in vitro protease inhibitor screening technique currently employed. Firstly, this assay is performed in vivo. Therefore, it can bypass the cumbersome protein purification step usually required in an in vitro assay. Secondly, the assay uses E. coli as a host, thus allowing for large library construction and screening as well as opting for cheap large-scale production. The isolation strategy is based on linking its function to the antibiotic resistance; i.e.,
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protection against protease catalysis will result in cell survival in the presence of selective media containing the β-lactam antibiotic so the assay can be conducted easily and inexpensively by plating cells on LB agar containing β-lactam antibiotics such as Amp or Carb. This method has potential for screening agents that inhibit proteolytic cleavage in a bacterial cell-based assay, which may find use in identifying, reconstituting, and characterizing protease inhibitors, identifying mutations on the substrate that can inhibit proteolytic cleavage, and drug screening. 
Localization of the Protease Activity Detector
Nonetheless, it is important to confirm that the cell resistance observed in the in vivo plating assay is actually based on the Tat transport of the uncleaved tripartite fusion protein. In this case, we investigated the localization of the tripartite fusion protein in each sample using anti-Bla antibody. As expected, the presence of tripartite protein fusion in the periplasm was only observed in the cells expressing inhibitory scFv. This is because scFv 35 binding to the protease can inhibit proteolytic cleavage allowing for the the periplasm. As the protection was not complete, some of the 31-kDa cleaved NS5B::Bla was also detected in the cytoplasm of the positive control. In the cells expressing scFv 53Y, the scFv inhibits NS3 catalysis; therefore, the tripartite fusion protein was cleaved leaving the part of NS5B::Bla in the cytoplasm, which was detected using anti-Bla antibody, while only the ssTorA::NS5A part was transported into the periplasm and was undetectable by anti-Bla antibody. Anti-FLAG antibody was used to detect the presence of the anti-NS3 scFvs. It is interesting to observe that the solubility of the scFv 53Y was a lot higher than that of the scFv 35, which was probably why the inhibition was quite successful, as we did not observe any tripartite fusion protein bands in the periplasmic sample when detecting with anti-Bla. 
Conclusion
Original techniques used for screening of NS3-inhibiting intrabodies required 2 steps, i.e., isolation by virtue of NS3 binding followed by the catalysis inhibition testing step. Gal-Tanamy et al. previously described a method that can be used to isolate NS3-inhibitory scFvs by virtue of their catalysis inhibition based on the activity of β-galactosidase [8] . This approach is based on color, i.e., blue-white screening of colonies plated on X-gal plates. Our approach is also a single-step in vivo method. However, by linking proteolytic inhibition to the antibiotic resistance, more colonies can be tested and isolation is still very convenient, as it only requires the plating of cells on to β-lactam antibiotic plates. Moreover, another isolation platform based on the Tat pathway has shown that the method favors selection of very stable protein interactions [11] , and thus it would be particularly useful for drug screening.
